What is CARDIOX?
CARDIOX operates as a sophisticated AI-powered biosensing platform, specializing in the synthesis of multi-modal data to deliver actionable insights into cardiovascular, metabolic, and behavioral health. By providing real-time metrics such as cuffless blood pressure, hydration levels, and stress monitoring, the platform addresses a critical gap in the health-tech market. Its versatile architecture supports a wide array of stakeholders, ranging from elite sports organizations and corporate wellness programs to clinical healthcare providers and academic researchers. Through its unique ability to facilitate both individual and group-level monitoring, CARDIOX is effectively redefining the standards for performance optimization and patient engagement in the digital health era.
How much funding has CARDIOX raised?
CARDIOX has raised a total of $12.6M across 4 funding rounds:
Private Equity
$786K
Debt
$652K
Private Equity
$8M
Unspecified
$3.2M
Private Equity (2009): $786K, investors not publicly disclosed
Debt (2010): $652K, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Unspecified (2014): $3.2M featuring Early Stage Partners and Reservoir Venture Partners
Key Investors in CARDIOX
Early Stage Partners
A venture capital firm established in 2001 that focuses on supporting technology companies in the Midwest by providing capital, strategic advice, and industry connections.
Reservoir Venture Partners
A specialized firm operating within the venture capital and private equity industry, known for its targeted investment approach in high-growth technology sectors.
Undisclosed Investors
What's next for CARDIOX?
With the successful closure of this major strategic investment, CARDIOX is strategically positioned to scale its operational footprint and enhance its AI-driven analytical capabilities. The company is expected to prioritize the expansion of its enterprise client base, focusing on the integration of its biosensing technology into broader healthcare ecosystems. Furthermore, the capital will likely be deployed to refine the accuracy of its non-invasive monitoring metrics, ensuring that the platform remains at the forefront of the rapidly evolving health-tech sector. As the firm continues to mature, its focus will shift toward long-term sustainability and the establishment of new industry benchmarks for real-time health data interpretation.
See full CARDIOX company page
